Figure 2.

Overexpression of hsa-miR-142-3p correlates with prolonged survival and chemosensitivity in non-small cell lung cancer (NSCLC) patients. Correlation between hsa-miR-142-3p expression and survival in SEER-Medicare lung squamous cell carcinoma (LUSC) patient population (A), and the dosage required for lethal concentration (LC₅₀) of paclitaxel in the NCI-60 (B). Kaplan–Meier analyses of patient stratification based on hsa-miR-142-3p expression in all SEER-Medicare LUSC patients treated with paclitaxel (C) and patients receiving only surgery and paclitaxel (D), CWRU patients receiving chemotherapy (E) or without chemotherapy (F), and MBRCC patients receiving chemotherapy (G) or without chemotherapy (H). Log-rank tests were used to assess the statistical significance.